ChartMill is a comprehensive online stock research platform designed to empower traders and investors with advanced tools for technical and fundamental analysis. The company provides a robust stock screener that allows users to filter thousands of stocks across major exchanges like NYSE, NASDAQ, and EURONEXT, using over 180 customizable technical and fundamental parameters to identify trading opportunities.
Globant's Q3 2025 results show a revenue beat but an earnings miss, causing a 4% stock drop. The company continues its strategic focus on AI-driven digital transformation.
GrabAGun's Q3 results show a strong revenue beat but a surprise earnings miss. The stock fell as investors focused on the quarterly loss despite solid sales growth and a strong cash position.
Beazer Homes Q4 earnings crush estimates with a 17.4% revenue beat and 33.8% EPS beat, driving shares up 8% as the homebuilder outperforms in a tough market.
RenovoRx Q3 2025 earnings show a 35% revenue miss, causing a stock drop. The clinical-stage biopharma provided a 2026 growth outlook to offset cash burn.
Marchex reports Q3 2025 results, missing revenue but meeting profit targets. The stock rose on news of its strategic Archenia acquisition and a positive 2026 growth outlook.
The Glimpse Group (VRAR) Q1 FY2026 revenue missed estimates, but its EPS loss was slightly better than expected. The company is focused on its Brightline Interactive spinoff and new government contracts.
AirJoule (AIRJ) stock rose after Q3 2025 results, beating EPS estimates with a smaller loss. The water-harvesting tech firm also announced key partnerships and progress toward 2026 commercialization.
Applied Materials (AMAT) narrowly beat Q4 FY2025 earnings and revenue estimates, achieving record annual results driven by AI and advanced semiconductor demand.
Trevi Therapeutics reported a narrower-than-expected Q3 2025 loss. The biopharma firm is preparing its Phase 3 program for Haduvio and has cash into 2028.
Precigen's Q3 2025 results show a huge revenue beat but a wider-than-expected loss. The key highlight is the full FDA approval and launch of its new therapy, PAPZIMEOS.
Hyperfine (HYPR) reported mixed Q3 2025 results, missing revenue and EPS estimates. The stock fell as its Q4 revenue guidance also trailed analyst expectations.
Net Power stock fell 12% after a strategic pivot to carbon capture tech, overshadowing an accounting-driven EPS beat and revealing a major asset impairment.
HeartBeam reports Q3 2025 results, missing EPS estimates. The pre-revenue firm focuses on FDA clearance for its cardiac tech, a key milestone expected by year-end.
BioAtla (BCAB) beat Q3 2025 EPS estimates, sending its stock up 7.5%. The biotech also gained FDA alignment for its Phase 3 trial in head and neck cancer.
TELA Bio reports Q3 2025 results with 9% revenue growth to $20.7M, missing estimates. The company improved its net loss and secured new financing for future expansion.
Rekor Systems (REKR) smashed Q3 2025 estimates with record revenue of $14.2M and a smaller-than-expected loss, sparking a positive after-hours market reaction.
WidePoint's Q3 2025 earnings show a revenue miss but strong sequential profit growth. The company secured major new contracts and maintains a $269M backlog for future growth.
Cytosorbents Q3 2025 earnings show a mixed quarter, beating EPS estimates but missing on revenue. The stock saw volatility despite a strengthened balance sheet.
Evolv Technology (EVLV) crushed Q3 2025 earnings estimates, reporting a surprise profit and strong revenue growth. The company also raised its full-year guidance.
Cibus (CBUS) Q3 2025 results show a narrower loss but a revenue miss, sending shares lower. The company highlights progress on key rice traits and cost-saving initiatives.
Jefferson Capital (JCAP) beat Q3 2025 earnings and revenue estimates, driven by record collections and deployments. The company also announced a major acquisition.
Nu Holdings (NU) Q3 2025 earnings smashed revenue estimates, reporting $4.17B. Customer growth and profitability surged, driving a 39% YoY net income increase to $783M.
Luminar (LAZR) Q3 2025 earnings beat revenue and EPS estimates, sending shares up 14%. The company is exploring strategic alternatives amid significant losses.
Origin Materials Q3 2025 results missed revenue and EPS estimates, causing a negative market reaction. The company maintains its long-term growth targets.
Let's have a look at what is happening on the US markets after the closing bell on Thursday. Below you can find the top gainers and losers in today's after hours session.
Intrigued by the market activity one hour before the close of the markets on Thursday? Uncover the key winners and losers of today's session in our insightful analysis.
Curious about the most active S&P500 stocks in today's session? Get insights into the stocks that are leading the way in terms of trading volume and market attention.
Looking for insights into the US markets in the middle of the day on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
SuperCom Ltd (SPCB) reported strong Q3 2025 results, beating EPS and revenue estimates with a surprise profit. The stock is consolidating as the market evaluates the record earnings.
Bitcoin Depot (BTM) beat Q3 2025 revenue and EPS estimates, with revenue up 20% year-over-year. The crypto ATM leader also reported a 139% surge in net income.
Ondas Holdings reports record Q3 2025 revenue, beating estimates by 41% and raising full-year guidance. The stock surged over 14% on the strong growth outlook.
PDS Biotech (PDSB) Q3 2025 earnings beat EPS estimates, sparking a major pre-market surge. The clinical-stage biotech also announced key progress for its lead cancer therapy.
Pelthos Therapeutics (PTHS) Q3 2025 results show a huge 66% revenue beat driven by strong demand for its new product ZELSUVMI, despite a significant EPS loss.
NIQ beats Q3 earnings expectations, sending its stock higher. The consumer intelligence firm reported strong revenue and a surprise profit, raising its full-year guidance.
American Shared Hospital Services (AMS) reported mixed Q3 2025 results, with strong EBITDA growth of 42.3% but a revenue miss versus analyst estimates.
